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Rituximab has been widely used for treatment-refractory pemphigus, but the 31 
experience as first line steroid-sparing agent is limited.1,2 In this retrospective study 32 
we assessed if early use of rituximab in the disease course would improve the long-33 
term clinical outcome.   34 
All pemphigus vulgaris and pemphigus foliaceus patients evaluated between January 35 
2008 and December 2016 at our institute and systematically treated with rituximab 36 
were included. Group A encompassed patients who received rituximab as a first line 37 
steroid-sparing adjuvant within 6 months of diagnosis without any conventional 38 
immunosuppresants. Group B consisted of patients with disease activity who received 39 
rituximab after failing corticosteroids/conventional immunosuppressants or for 40 
relapse after them. Patients in both groups were treated with two infusions of 1000 mg 41 
rituximab, two weeks apart. Patients who relapsed or failed to achieve clinical 42 
remission (CR)3  in 6 months were re-treated with a single infusion (1000mg) of 43 
rituximab.. In addition, patients in both groups received oral corticosteroids with a 44 
starting dose of prednisolone between 0.5 to 1 mg/kg  with invariably a quick taper 45 
and withdrawal of the corticosteroids within 6 months depending on the severity of 46 
the disease and clinical judgement.  47 
The primary aim was to compare the efficacy between the two groups in terms of 48 
achieving CR off treatment. The secondary outcomes were CR on minimal therapy, 49 
relapse rate, requirement of repeat infusions and rituximab-related adverse events.3 50 
The baseline characteristics of the two groups are summarized in Table 1. In group A, 51 
7/9 (estimated cumulative rate 87.5%) patients and 12/20 (66.2%) patients in group B 52 
achieved CR off therapy (p=0.01). After accounting for the effect of disease duration, 53 
the hazard ratio between the two groups was still statistically significant (HR: 6.10, 54 
95% CI: 1.52 - 24.44, p=0.01).  55 
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When both minimal therapy and off therapy was considered, CR was achieved by 8/9 56 
(estimated cumulative rate 100%) patients in group A and 19/22 (92.9%) patients in 57 
group B without any statistically significant difference (Table 2).  Relapse was seen 58 
in 4/9 (44.4%) and 7/22 (31.8%) patients in group A and B respectively. Five/9 59 
(55.6%) patients in group A and 6/22 (35.5%) patients in group B were administered 60 
repeated infusions of rituximab, with three (33.3%) and two (9.1%) patients 61 
respectively receiving two or more repeat infusions. No significant difference was 62 
found between the two groups regarding the time to first relapse (p=0.33). 63 
In our study CR off treatment was more likely to be achieved by patients receiving 64 
rituximab earlier in the disease (<6 months) and as first-line steroid sparing adjuvant. 65 
Even when accounting for prolonged disease durations, our results were still 66 
significant. Given the limits of our sample size, we were unable to account for 67 
additional potential cofounders such as disease subtype or the use of different 68 
adjuvant therapies. However, previous analyses have failed to show any effect of 69 
these confounders on clinical outcomes.4 Thus, it is unlikely they contributed to the 70 
difference in our observed responses. Noteworthy, despite the differences in early 71 
outcome, there was no difference between the groups in any of the secondary end 72 
points. The higher requirement of repeat infusions in group A is skewed by its small 73 
sample size and two of the patients requiring re-treatment for failure to achieve CR.  74 
A prospective multicentre study encompassing 91 pemphigus patients has shown that 75 
first-line use of rituximab in combination with short-term prednisone allows to 76 
achieve CR off treatment in a three times greater portion of patients than using 77 
prednisone alone and was associated with significantly fewer grade 3 and 4 side 78 
effects.5 These findings support the use of rituximab with low dose corticosteroids as 79 
first-line regimen in pemphigus.  80 
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Abbreviation  81 
CR: complete remission 82 
HR: hazard ratio  83 
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Table 1.  Demographics and clinical characteristics of the included patients 103 
 104 
 Group A 
(N=9) 
Group B 
(N=22) 
P** 
N* % N* % 
Sex M 3 33.3% 8 36.4% 1 
F 6 66.7% 14 63.6%  
Age (years) Mean, SD 62.5 17.9 54.8 16.7 0.66 
Age at diagnosis (years) Mean, SD 62.2 18.0 51.3 16.4 0.24 
Disease duration prior to 
rituximab (weeks) Mean, SD 15.1 7.1 180.8 142.5 
<0.001 
Type of pemphigus PV 4 44.4% 15 71.4% 0.22 
PF 5 55.6% 6 28.6%  
Previous treatments  Azathioprine - - 14 66.7% - 
MMF   5 23.8%  
Cyclophosphamide   1 4.8%  
Methotrexate   1 4.8%  
Dapsone   2 9.5%  
Others   1 4.8%  
 Number of previous 
treatments 
0 - - 1 4.8% - 
1   16 76.2%  
2 or  more   4 19.0%  
Baseline cutaneous 
severity (ABSIS) Mean, SD 9.7 10.7 7.7 7.5 
1 
Baseline mucosal 
severity*  
None 5 55.6% 6 28.6% 0.23 
Mild (<5% area involved) 1 11.1% 10 47.6%  
Moderate (5%-30% area 
involved) 2 22.2% 3 14.3% 
 
Severe (>30% area 
involved) 1 11.1% 2 9.5% 
 
Dsg 1 Negative 3 33.3% 6 27.3% 0.69 
0 - 99 2 22.2% 9 40.9%  
100+ 4 44.4% 7 31.8%  
Dsg 3 Negative 4 44.4% 6 27.3% 0.55 
0 - 99 3 33.3% 7 31.8%  
100+ 2 22.2% 9 40.9%  
PV: pemphigus vulgaris; PF: pemphigus foliaceus; SD: standard deviation; Dsg: Desmoglein ELISA 105 
values in U/ml ; MMF: mycophenolate mofetil;  106 
* Numbers may not add up to the total due to missing data 107 
** Fisher’s exact test or Mann-Whitney U test for categorical and continuous variables, respectively 108 
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Table 2.  Cumulative rates and hazard ratios of patients achieving complete remission (CR) 109 
and of patients remaining in CR, overall and by kind of rituximab treatment 110 
 Group A Group B P* 
HR, A vs. B 
(95% CI) 
P** 
CR off therapy, % (95% CI) 87.5% (64.6 - 100) 
66.2% (43.7 - 
88.7) 0.01 
6.10 (1.52 - 
24.44) 0.01 
N patients 9 20    
N events 7 12    
Max time, weeks 128.1 414.9    
Median time to achieve CR, 
weeks (95% CI) 
39.7 (30.4 - 
49.0) 
72.3 (0 - 
184.7)    
CR on minimal therapy  
and off therapy, % (95% CI) 
100% (NC) 92.9% (80.6 - 100) 0.46 
1.03 (0.35 - 
3.07) 0.96 
N patients 9 22    
N events 8 19    
Max time, weeks 119.7 213.9    
Median time to achieve CR, 
weeks (95% CI) 
30.9 (13.8 - 
47.9) 
29.7 (26.5 - 
32.9)    
Patients remaining in CR, % 
(95% CI) 
33.3% (0 - 
70.9) 
61.1% (38.6 - 
83.6) 0.33 
1.19 (0.28 - 
5.04) 0.82 
N patients 8 19    
N events 4 7    
Max time, weeks 127.4 396.0    
Median survival time, weeks 
(95% CI) 
51.9 (19.4 - 
84.3) NC    
CI: confidence interval,  HR: hazard ratio,  NC: not computable 111 
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* Log-rank test 112 
** P-value from Cox regression models including disease duration prior to rituximab as adjustment 113 
variable 114 
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